Pharmaceutical technology innovation strategy based on the function of blood transport proteins as DDS carriers for the treatment of intractable disorders and cancer

Research output: Contribution to journalReview articlepeer-review

Abstract

Blood transport proteins are biogenic molecules with unique and interesting inherent characteristics that make up living organisms. As the utilization of their inherent characteristics can be a groundbreaking strategy to resolve and improve several clinical problems, attempts have been made to develop pharmaceutical and biomedical preparations based on blood transport proteins for the treatment and diagnosis of disorders. Among various blood transport proteins, we focus on the immense potential of hemoglobin and albumin to serve as carriers of biomedical gases (oxygen and carbon monoxide) and anticancer agents (low-molecular compounds and antisense oligodeoxynucleotides), respectively, for the development of innovative drug delivery systems (DDS) to treat intractable disorders and solid cancers. In this review, I introduce the pharmaceutical technology, strategies, and application of DDS carriers that have been designed on the basis of the structure and function of hemoglobin and albumin. In addition, the prospect of using hemoglobin and albumin as materials for DDS carriers is discussed.

Original languageEnglish
Pages (from-to)1815-1822
Number of pages8
JournalBiological and Pharmaceutical Bulletin
Volume43
Issue number12
DOIs
Publication statusPublished - 2020 Dec 1

Keywords

  • Albumin
  • Cancer
  • Drug delivery
  • Hemoglobin
  • Liposome

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Pharmaceutical technology innovation strategy based on the function of blood transport proteins as DDS carriers for the treatment of intractable disorders and cancer'. Together they form a unique fingerprint.

Cite this